SCHEMBL5844181

SCHEMBL5844181

COc1cc[c]c(C(N)=O)c1-c1ccc(SC)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.35
GAA P10253 2/20 0.35
PLAU P00749 1/20 0.34
ALDH1A1 P00352 3/20 0.33
POLB P06746 3/20 0.33
HPGD P15428 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
MAPT P10636 3/20 0.32
KDM4E B2RXH2 2/20 0.32
NPC1 O15118 4/20 0.32
L3MBTL1 Q9Y468 4/20 0.32
RAB9A P51151 3/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
CYP1A1 P04798 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP1B1 Q16678 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5841892 0.85 PARP10 (0.45) GAAPLAUALDH1A1LMNAL3MBTL1
SCHEMBL6697981 0.83 FABP3 (0.40) POLBSMN1; SMN2LMNATSHRMAPT
SCHEMBL5843618 0.83 RAB9A (0.36) ARGAAALDH1A1SMN1; SMN2MAPT
SCHEMBL6254788 0.83 FABP4 (0.42) ALDH1A1POLBSMN1; SMN2LMNATSHR
SCHEMBL6259927 0.75 PARP1 (0.47) PLAUSMN1; SMN2LMNAL3MBTL1
SCHEMBL5843344 0.71 AKR1C3 (0.47) GAAALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL27773949 0.71 FABP4 (0.47) ALDH1A1POLBHPGDSMN1; SMN2LMNA
SCHEMBL7488931 0.68 CYP1A1 (0.36) ALDH1A1HPGDSMN1; SMN2LMNATSHR
SCHEMBL11538213 0.66 CA12 (0.43) GAAALDH1A1POLBSMN1; SMN2LMNA
SCHEMBL980742 0.64 ALDH1A1 (0.44) ARGAAALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 US claimed
EP-1294688-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2003-03-26 EP claimed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 US claimed
WO-2001094312-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-12-13 WO claimed
US-7071332-B2 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. (US) 2006-07-04 US disclosed
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 US disclosed
US-6706709-B2 TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER SUGEN, INC. 2004-03-16 US disclosed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 AR 2826/4885GAA 714/4885PLAU 4054/4885
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 AR 2826/4885GAA 714/4885PLAU 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.